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ABSTRACT
We created the PDX Network (PDXNet) portal (https:
//portal.pdxnetwork.org/) to centralize access to the
National Cancer Institute-funded PDXNet consortium resources, to facilitate collaboration among researchers and to make these data easily available for
research. The portal includes sections for resources,
analysis results, metrics for PDXNet activities, data
processing protocols and training materials for processing PDX data. Currently, the portal contains
PDXNet model information and data resources from
334 new models across 33 cancer types. Tissue samples of these models were deposited in the NCI’s
Patient-Derived Model Repository (PDMR) for public access. These models have 2134 associated sequencing files from 873 samples across 308 patients,

* To
†

which are hosted on the Cancer Genomics Cloud
powered by Seven Bridges and the NCI Cancer Data
Service for long-term storage and access with dbGaP
permissions. The portal includes results from freely
available, robust, validated and standardized analysis workflows on PDXNet sequencing files and PDMR
data (3857 samples from 629 patients across 85 disease types). The PDXNet portal is continuously updated with new data and is of significant utility to the
cancer research community as it provides a centralized location for PDXNet resources, which support
multi-agent treatment studies, determination of sensitivity and resistance mechanisms, and preclinical
trials.
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GRAPHICAL ABSTRACT

Patient-derived Xenograft (PDX) models are cancer models that support personalized medicine research and preclinical and co-clinical trials (1–5). Specific PDX research
areas include the study of sensitivity and resistance mechanisms, evaluation of new treatment options, and the study
of tumor heterogeneity. The PDX research community is
rapidly growing, with PDX-generated data being the preferred support for proposing human clinical trials (6). In
2017, the National Cancer Institute (NCI) funded the PDX
Development and Trial Centers (PDTC) research network
(PDXNet, https://www.pdxnetwork.org/) consortium to accelerate PDX research by developing new PDX models
across cancer types, identifying new multi-agent treatments
to bring forward into clinical trials, generating complementary RNA-Seq and whole-exome sequencing data, and increasing the ethnic diversity of publicly available PDX models.
PDXNet was also charged with developing collaborative research projects involving the six different PDTCs
to advance PDX science. Each of the PDTCs came into
PDXNet with its own home-grown data standards, data analytic pipelines and workflows. To facilitate collaboration,
the disparate processes and databases required harmonization at many different steps, so that data from centers could
be combined and analyzed efficiently. The harmonization
goal was achieved through the creation of the PDXNet portal and the analytical tools within it. The PDXNet portal
resources created by this effort enabled the successful completion of several collaborative research projects (7–10) and
are supporting many others.
In addition to facilitating PDXNet research, a further
benefit of the PDXNet portal is to make the PDXNetgenerated data and workflows of the PDXNet portal available as a public resource. These data will support cancer
research by increasing the quantity and diversity of PDX
data available and decreasing the effort required to analyze PDX sequencing data. We present the PDXNet portal as a utility for PDXNet data for the larger scientific
community.
The PDXNet portal is already supporting the goals of
data harmonization, discovery, generation and analysis. To
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INTRODUCTION

demonstrate the utility of the portal resource, we highlight
an in progress PDXNet pilot project. Initial review of model
metadata identified the need for standardized ancestry information across the PDTCs. For this project, the analyst
accessed the metadata (downloadable from the PDXNet
portal and described below) to identify related sequencing
data from PDX model IDs. For each available model, the
analyst then generated standardized ancestry estimates with
a published ancestry inference workflow (see result section
for details). These ancestry estimates were then added to
the portal metadata in a searchable interface. Moreover, we
created a portable and reproducible version of the publish
ancestry inference workflow, allowing other researchers to
use and independently validate once linked to the PDXNet
Portal.
There are several existing public PDX resources that
complement the PDXNet portal. Launched in 2012, the
NCI Patient-Derived Model Patient Repository (PDMR;
11) collects and develops PDX models and associated standardized sequencing data (RNA-Seq and whole-exome),
with the goal of supporting academic and industry research. The PDMR maintains a publicly available database
of models and a File Transfer Protocol (FTP) site for accessing sequencing data (https://pdmr.cancer.gov/database/
default.htm). Another resource is PDXFinder (https://
www.pdxfinder.org, 12). PDXFinder is an online resource
that aims to harmonize internationally generated PDX
models and their associated metadata. PDXFinder is a collaboration between the European Molecular Biology Laboratory’s European Bioinformatics Institute (EMBL-EBI)
and the Jackson Laboratory. A key component of data harmonization in PDXFinder is the PDX minimal information standard (PDX-MI; 13), which allows for standardized
PDX information exchange. PDXFinder employs PDX-MI
to support complex model searches that enable users to
identify model descriptions and subsequently link to model
information and a request form. EuroPDX is a consortium
of eighteen non-profit cancer institutes that collaborate and
coordinate PDX model development and access to improve
cancer patients’ standard of care. Next, the EuroPDX Data
Portal (https://dataportal.europdx.eu/) is a resource that
provides information about PDX models generated by EuroPDX researchers and clinicians. Lastly, the Baylor College of Medicine PDX portal (https://pdxportal.research.
bcm.edu/) provides access to breast cancer, leukemia, pediatric liver cancer, pancreatic cancer and sarcoma model
collections.
The primary aim of the PDXNet portal is to support
the Cancer Moonshot (14) model and data sharing goals
(15). The PDXNet portal facilitates the distribution of resources, complementary data analyses and developed tools.
The resources generated include data collections and standardized bioinformatics workflows. Complementary data
analyses such as data quality control analyses that support
data-use are also available from the portal. Tools developed
to support the use of the data (e.g. workflow cost estimation) are also accessible. Integration with the NCI Cloud
Resource, the Cancer Genomics Cloud powered by Seven
Bridges (CGC; 16), allows approved researchers to directly
analyze PDXNet data or use developed workflows on private data.
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This manuscript details the PDXNet portal features that
provide a gateway for identifying and accessing resources
generated by the PDXNet community.
MATERIALS AND METHODS
Portal features

PDXNet portal landing page
The PDXNet portal landing page includes an overview and
summary panel of contents (Figure 1). The portal overview
identifies the primary PDXNet funding sources and participants. In summary, the NCI Cancer Therapy Evaluation
Program (CTEP) funds four PDTCs and the PDX Data
Commons and Coordinating Center (PDCCC), whereas the
NCI Center to Reduce Cancer Health Disparities funds two
PDTCs (see Table 1 for additional details). The portal directs questions and requests for additional information to
the PDXNet website at https://pdxnetwork.org.
The data summary panel on the right side of the screen
allows the reader to review model and data summaries and
the portal update timeline. The data summary panel lists
the number of PDTCs contributing data, the number of files
uploaded by the PDTCs and available from the PDMR, the
total number of models, and the number of cancer types represented in those models. Dropdown menus on the top bar
of the landing page include ‘Resources’, ‘Analysis’, ‘Tools’,
‘Help’, ‘About’ and ‘Contact’, which are further summarized below. Buttons at the bottom left provided quick access to PDXNet model information, data resources, and
data search. Tabs associated with the right-hand data summaries allows the reader to review summary figures for PDX
Models by cancer type and contributing PDTC, sequencing
files by experimental strategy, ancestry and the Portal Update Timeline.
Resources tab
The PDXNet Portal Resources tab includes the following
links to separate pages: PDXnet models, Data Collection,
Interactive Exploration, and Workflows, and subpages are
described in subsequent sections.
PDXNet models. The PDXNet portal models tab summarizes verified model submissions to the PDMR made
by each PDTC (Supplementary Figure S1). The PDXNet
models are a primary consortium deliverable. Each model
submitted by a PDTC to the PDMR includes a completed
model submission form that details the general PDX information, model-specific information, and tissue implantation details. Metadata are consistent with the PDX-MI

Data search. The PDXNet Portal data search page allows
users to query across data types, and harmonizes metadata
across model information, sequencing files and image files.
Users query from data source, samples and disease types.
Query results are shown in Venn diagrams and users can
download data tables organized by sample, model or patient
at the bottom of the page. The data search feature specific
currently queries across with corresponding PDMR image,
RNA-seq and WES data.
Data collection. The PDXNet Portal Data Collection tab
summarizes sequencing data from the PDMR and PDTCs,
and image files.
Data collection, PDMR. This sub-tab summarizes sequencing data transferred from the PDMR FTP server to
the CGC as of December 2021 (Supplementary Figure S2).
The PDMR generates whole-exome and transcriptome sequencing data from models submitted according to tissue
collection best practices and model quality control practices
(11). Molecular characterizations include whole-exome sequencing and gene expression profiling. We processed the
PDMR sequencing data with standardized workflows as for
the PDTC data.
Data collection, PDTC. This sub-tab summarizes
sequencing data submitted by the PDTCs for intraconsortium sharing and for public sharing (Figure 2). The
PDXNet Data Collection, PDTC tab presents the core
PDXNet sequencing data set. We processed submitted
sequencing data with standardized workflows (e.g. whole
exome capture) according to a written standard operating
procedure provided on the CGC. See the workflow section
for description of the workflows used for standardized
processing.
PDXNet researchers contributed 2134 total sequencing
files that include both whole-exome (74.5%, 11 590) and
RNA-Seq (25.5%, 544) data. Six institutional contributors
submitted 873 samples from 308 patients. The sequencing
sample types include PDX (56.0%, 1194), tumor (25.7%,
548) and normal (18.4%, 392). The most prevalent diseases
represented among the samples include breast (27.5%, 586),
skin (18.8%, 402), lung (17.1%, 364) and colon (8.4%, 180).
Metadata provided by centers did not include disease information for 0.9% (20) samples (see Table 3 for additional
information).
The PDMR sequencing dataset on the CGC includes 14
506 paired-end sequencing files that include both wholeexome (52.2%, 7576) and RNA-Seq (47.8%, 6926) data. The
data set includes 3857 samples from 629 patients covering
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The PDXNet portal is a publicly accessible website (https:
//portal.pdxnetwork.org/) with the primary function of providing access to the PDXNet models and information on
how to obtain sequencing data. We extended the portal’s
primary mission beyond PDXnet to incorporate additional
resources, including supporting access to the PDMR sequencing file data set, a PDXNet hematoxylin and eosin
stain image data set, and tumor volume data. Below, we describe the features and sections of the Portal in detail.

and the PDMR data format. The metadata includes model
id information to facilitate search and cross referencing to
related PDMR models.
To date, PDXNet researchers have submitted
334 models to the PDMR across 33 cancer types.
The most prevalent model cancer types include invasive breast carcinoma (30.8%, 103), melanoma
(20.1%, 67), adenocarcinoma––colon (12.3%, 41), and
adenocarcinoma––pancreas (7.8%, 26). See Table 2 for
additional details.
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85 disease types. The sequencing sample types include PDX
(81.4%, 11 808), primary tumor (5.6%, 812), pdc: mixed tumor culture (4.7%, 684) and normal germline (4.4%, 644).
The most prevalent diseases represented among the samples include colon (19.2%, 2,780), pancreas (9.2%, 1,332),
melanoma and (6.5%, 938). Due to the size and cost associated with data transfers, synchronization between the
PDMR sequencing database and the CGC dataset is done
periodically. The PDMR data webpage has the most updated list of available PDMR sequencing data processed
with standardized PDXNet workflows.

by the PDMR (Supplementary Figure S3). The PDMR
image data on the CGC includes 194 images scanned
from PDX (96.4%, 187) and primary tumors (3.6%, 7).
The images correspond to 194 samples taken from 27
patients across 4 disease types. The PDX passages ranged
from P0 to P6 with the top four passages corresponding
to P1(40.6%, 73), P0 (25.0%, 45), P2 (22.8%, 41) and P3
(7.2%, 13). The PDXNet Portal currently supports 43
metadata fields that data submitters can populate upon
submission (See Supplementary Table S1 for the complete
list).

Data collection, Image. This sub tab summarizes
hematoxylin-eosin stain (H&E) image data provided

Interactive exploration. The PDXNet Portal data explorer
allows users to interactively create summary tables from
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Figure 1. PDXNet Portal Landing Page Views from the PDXNet Portal Landing Page. (A) The initial PDXNet Portal Landing Page. (B) Experimental
strategies (whole-exome and RNA-Seq) for the PDXNet (magenta) and PDMR (gray) sequencing datasets. (C) Computed ancestry in a pie chart. Ancestry
is classified in the following categories: European (EUR-Red), African (AFR-Blue), American (AMR-Purple), Mixed (MIX-Orange), East Asian (EASLight Purple), South Asian (SAS-Yellow).
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Table 1. PDXNet Development and Trial Centers (PDTC) and the PDX
Data Commons and Coordinating Center (PDCCC)

data processing steps for each workflow is provided on the
CGC in the respective description section.

PDXNet
PDX Development and Trials Centers (PDTC)
HCI-BCM*
Huntsman Cancer Institute and Baylor College
of Medicine
MDACC
MD Anderson Cancer Center
WUSTL*
Washington University at St. Louis
WISTAR*
Wistar Institute and MD Anderson Cancer
Center
BCM&
Baylor College of Medicine
UCDAVIS&
The University of California at Davis

* NCI
& NCI

Cancer Therapy Evaluation Program Funding
Center to Reduce Cancer Health Disparities Funding

The PDXNet Portal Analysis tab includes the following
menu options: Ancestry Analysis, HRD-MSI-TMB Analysis, Tumor Volume Analysis, QC Analysis and Variant
Search. These sections include metrics derived from primary data sources and are described in the results section below in more detail. These results were generated
from standard processing analysis workflows or through
PDXNet research activities (8), and we provide these analyses to support independent research by the broader research
community.
Tools tab

PDMR and PDTC sequencing file metadata (Supplementary Figure S4). The interactive table supports 10 table and
chart types including simple tables, bar charts, line charts,
and heat maps (see Supplementary Table S2 for full list).
Interactive tables also support 22 data summary options including count, sum, average and variance (see Supplementary Table S3 for the full list). The user drags and drops from
20 metadata fields to the table type area to construct the
table. Metadata field examples include contributor, sample
type, experimental strategy and passage (see Supplementary
Table S4 for complete list).
Workflows. The PDXNet Portal Workflows page summarizes analysis workflows developed by the PDXNet community (Supplementary Figure S5). The CGC based analysis workflows are a significant resource developed by the
PDXNet community, allowing for reproducible and standardized analysis of PDX data (8). We selected workflows
for standard consortium-wide data processing and public
release from those submitted by each PDTC after benchmarking with simulated and experimentally derived PDX
data (8). Since the initial public release, we have restructured the workflows to efficiently process normal (tissue),
tumor-only and tumor-normal data. These workflows are
implemented on the CGC using the Common Workflow
Language (CWL; 17) with Docker containerized tools,
which allows for easy sharing and analysis reproducibility. The PDXNet consortium developed a set of 15 workflows validated for processing of both whole-exome and
RNA-Seq data (See Supplementary Table S5). We are sharing these validated and tested workflows with the broader
community via the CGC Public Apps Gallery (https://
cgc.sbgenomics.com/public/apps#q?search=pdx). The use
of CWL allows these workflows to be portable to any CWLcompliant execution environment. The workflows collectively facilitate the analysis of whole-exome or RNA-Seq
data via mouse read disambiguation, read alignment, variant calling or transcript quantification, and sample and cohort level quality control. For whole-exome data, we also
compute copy number variation (CNV), tumor mutational
burden (TMB), microsatellite instability (MSI) and homologous recombination deficiency (HRD) during standardized processing. A full explanation of inputs, outputs and

The PDXNet Portal Tools tab includes the following
choices: Workflow Cost Prediction, Metadata -Create,
Metadata -Validate. These tools, described in the following
sections, support present and future PDXNet and other independent general research activities.
Workflow cost prediction. The Workflow cost prediction
tool allows users to estimate the cost of processing their
samples on the CGC with the PDXNet workflows. This tool
uses prediction models (gradient boosting trees; 18) generated from 7000 workflow runs. The user can select either
whole-exome or RNA-Seq workflows and provide the number and optionally size of files to process. The calculator
computes the storage and computation cost for processing
the user defined dataset. The estimated costs assume the
workflows were run on the CGC using spot instances. We
expect the tool to allow users to estimate data storage and
computational cost for their own analyses allowing for estimating grant budgets and budgeting lab expenses.
Create. The generate metadata tab allows users to interactively generate a PDX minimum information metadata sheet (PDX-MI). As described above, the PDXFinder
working group developed the PDX-MI as a standard for
exchanging PDX information among institutions. The generate metadata tab allows the user to create a PDX-MI
spreadsheet by stepping through data entry dialog boxes.
The interface supports entry of patient information, treatment information, tumor information, model and sequencing metadata. The user downloads the spreadsheet upon
data entry completion, and no information is stored permanently on the PDXNet Portal site.
Metadata, validate. The validate metadata tab allows
users to upload and validate a PDX-MI metadata spreadsheet. The user can review uploaded contents at the bottom
of the page. The validation verifies that required metadata
fields are present and that entries are valid. The validation
feature generates a summary of required fields that includes
percent completed and most common data entry per field.
The validation feature reduces the amount of time necessary
to review and check submitted PDX-MI spreadsheets.

Downloaded from https://academic.oup.com/narcancer/article/4/2/zcac014/6572305 by guest on 20 May 2022

PDX Data Commons and Coordinating Center
JAX-SB*&
Jackson Laboratory and Seven Bridges

Analysis tab
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Table 2. PDX models generated by PDX Development and Trials Centers
MDACC

WUSTL

Wistar

UC Davis

BCM

Totals

Breast
Head and Neck
Digestive/Gastrointestinal
Endocrine and Neuroendocrine
Musculoskeletal
Respiratory/Thoracic
Skin
Genitourinary
Gynecologic
Unknown Primary

78
0
0
0
0
0
0
0
0
0

12
0
50
2
1
30
3
0
3
0

2
2
44
0
4
1
2
5
0
0

0
0
0
0
0
0
63
0
0
1

0
0
3
0
0
2
0
10
0
0

16
0
0
0
0
0
0
0
0
0

108
2
97
2
5
33
68
15
3
1

Total

78

101

60

64

15

16

334

HCI-BCM: Huntsman Cancer Institute and Baylor College of Medicine, MDACC: MD Anderson Cancer Center, WUSTL: Washington University at St.
Louis, Wistar: The Wistar Institute, UC Davis: University of California Davis, BCM: Baylor College of Medicine

Portal design and organization
The PDXNet Portal is designed to support coordination
with other resources, including the PDMR, the CGC and
the NCI Cancer Data Service (CDS; https://datacommons.
cancer.gov/). Currently, the PDXNet portal references
PDMR model information, genomic, transcriptomic and
tumor volume response data used in PDXNet research activities. The CGC serves as a PDXNet data staging area supporting data harmonization, standardized data processing
and research activities. The PDXNet Portal supports submission of sequencing data to the CDS to provide long-term
research access to PDXNet data resources. The CDS is part
of the NCI Cancer Research Data Commons which aims
to store data resources generated by NCI-funded research.
The CDS is available from across the NCI data infrastructure through a dbGaP access mechanism. The PDXNet
portal augments the dbGaP submission process, through
an administrative feature for generating data reports and
through a dbGaP submission tool written to support CDS
submissions. The PDXNet Portal aims to use data standards when they exist, supporting both the PDX-MI standard (13) and the PDMR data structures (11). These existing data structures allow for collaboration and information
sharing with existing PDX resources.
Implementation
The backend of the PDXNet Portal is an R-Shiny app
hosted on a cloud-based server. The portal uses the PDMR
and PDX-MI metadata standards. The PDMR and PDXMI standards allow us to harmonize data across sources,
quickly import data from the PDMR and other data
sources, and exchange information with other PDX related
portals. We also collect additional metadata required to facilitate computation on the CGC, including omics-related
information. We use the Cancer Therapy Evaluation Program (CTEP) disease classification to standardize disease
entries although we initially accepted institutionally defined
disease classification. In the cases where a standard does not
exist; we collect sufficient metadata required to display and
process the data source. For example, we take a minimalistic approach to managing tumor volume and H&E image data. Several PDXNet teams are working toward the
development of best practices for these data types. Until

these best practices are published, we will evolve these operational standards to support harmonization and analysis.
The PDXNet Portal team updates information on the
portal semi-automatically using the same data model as
the PDMR, allowing PDXNet to sync with PDMR model
information. The PDMR provides regular updates to
PDXNet on PDTC model submissions to update the PDX
Model’s page. We receive sequencing data upload updates
from the PDTCs and the PDMR, and we have developed scripts for extracting PDXNet standardized processing results, allowing for quality control information and
computational metrics to be tabulated for semi-automated
PDXNet Portal updates. The PDXNet Portal source code
will not be made publicly available for security reasons. Future PDXNet Portal versions will support controlled access
sign-in to provide links to controlled files.
RESULTS
All analysis subsections described below can be found as
selections under the ‘Analysis’ tab in the menu bar of the
portal page.
Ancestry analysis
The PDXNet Portal Ancestry Analysis page summarizes
genetic ancestry analysis for datasets on the portal (Supplementary Figure S6). We compute ancestry with SNPweight
(19) using a reference dataset generated from the 1000
Genomes Project Phase III (20). We classify each sample
into one of five categories, which correspond roughly to the
concept of ‘continental ancestry’ (21). These categories include European (EUR), African (AFR), American (AMR),
East Asia (EAS) and South Asian (SAS). Samples that
could not be confidently assigned to one of these categories
are labeled Mixed (MIX). On the left side of the page, ancestry data filters allow the user to select the data contributors, ancestry and disease type. Applying the selected filter
to the data regenerates the two summary figures. The first
summary figure is a bar chart that shows the ancestry distribution for the selected disease types. The second summary
figure shows a pie chart with each slice corresponding to the
ancestry types chosen. Supplementary Table S6 shows the
summary of ancestry estimation from PDX Models submitted to the PDMR.
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Figure 2. PDXNet sequencing data page on the PDXNet Portal Components of the PDXNet sequencing data page. (A) Panel shows summary statistics
including number of sequencing files (green), contributors (yellow), total samples (orange) and total patients (blue). Also, shown are donut plots for
contributors, sample types, disease type, experimental strategy, WES contributors and RNA-Seq contributors. (B) Panel shows metadata for the PDXNet
sequencing data in a spreadsheet format. The interface supports searching and sorting metadata. Users can copy, print, and download metadata into
accessible formats.
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Table 3. Sequencing data files generated by PDX Development and Trial Centers
BCM-HCI
N = 408

MDACC
N = 418

UC Davis
N = 48

WISTAR
N = 382

WUSTL
N = 878

Experimental strategy n (%)
RNA-Seq
WES

544 (25%)
1590 (75%)

102 (25%)
306 (75%)

6 (1%)
412(99%)

32 (67%)
16 (33%)

144(38%)
238(62%)

260(30%)
618(70%)

Disease type, n (%)
Bladder
Blood
Bone
Breast
Colon
Gastrointestinal
Head and Neck
Kidney
Lung
Ovarian
Pancreas
Rectum
Skin
Soft Tissue Neoplasm
Unknown

114(5.0%)
84(4.0%)
8(0.4%)
586(27%)
180(8.4%)
34(1.6%)
24(1.1%)
58(2.7%)
364(17%)
8(0.4%)
174(8.1%)
22(1.0%)
402(19.0%)
56(2.6%)
20(0.9%)

2(<0.5%)
0(0%)
0(0%)
382(93%)
4(1.0%)
0(0%)
0(0%)
0(0%)
0(0%)
0(0%)
0(0%)
0(0%)
0(0%)
0(0%)
20(5.0%)

4(1.0%)
84(20.0%)
0(0%)
0(0%)
8(2.0%)
0(0%)
0(0%)
0(0%)
322(77%)
0(0%)
0(0%)
0(0%)
0(0%)
0(0%)
0(0%)

48(100%)
0(0%)
0(0%)
0(0%)
0(0%)
0(0%)
0(0%)
0(0%)
0(0%)
0(0%)
0(0%)
0(0%)
0(0%)
0(0%)
0(0%)

4(1%)
0(0%)
0(0%)
0(0%)
0(0%)
0(0%)
0(0%)
0(0%)
0(0%)
0(0%)
0(0%)
0(0%)
370(97%)
0(0%)
0(0%)

56(6.4%)
0(0%)
8(0.9%)
204(23%)
160(18%)
34(3.9%)
24(2.7%)
58(6.6%)
42(4.8%)
8(0.9%)
174(20%)
22(2.5%)
32(3.7%)
56(6.4%)
0(1.7%)

Sample type, n (%)
Normal
PDX
Tumor

392(18%)
1,194(56%)
548(26%)

32(8%)
328(80%)
48(12%)

142(34%)
146(35%)
130(31%)

0(0%)
0(0%)
48(100)

0(0%)
202(53%)
180(47%)

218(25%)
515(59%)
142(16%)

HCI-BCM: Huntsman Cancer Institute and Baylor College of Medicine, MDACC: MD Anderson Cancer Center, WUSTL: Washington University at St.
Louis, Wistar: The Wistar Institute, UC Davis: University of California Davis, BCM: Baylor College of Medicine

HRD-TMB-MSI analysis
The PDXNet Portal HRD-HSI-TMB analysis page allows the user to filter and summarize three computational metrics generated from whole-exome sequencing
data by PDXNet standardized processing (Figure 3). The
three computed metrics are homologous recombination
deficiency (HRD), tumor mutational burden (TMB) and
microsatellite instability (MSI). HRD is computed with
ScarHRD (22) for matched normal data. TMB is calculated
as the number of coding mutations that meet all quality criteria per Mb of the genome. Quality criteria are assessed using coverage, allele frequency, mapping quality and strand
bias. Variants included in the calculation are somatic and
non-polymorphic, and are defined in SnpEff (23) as ‘high’
or ‘moderate’ functional impact. As only a portion of the
genome was sequenced, genome coverage (Mb) is calculated
from the input target coverage BED file. MSI is calculated
with MANTIS (24) for samples with matched normal data
and calculated with MSIsensor2 (25) for tumor-only samples. For each metric, users can set data filters for the visualizations. The data filters, on the left side of the page, allow
the user to select data contributor, sample type, experimental strategy and disease type. Applying the selected filter to
the data generates a boxplot chart displaying the selected
metrics for each disease type chosen (Figure 3).
Tumor volume analysis
The PDXNet Portal Tumor Volume Analysis Page allows
the user to visualize raw tumor volume growth data provided by the PDTCs (Figure 4). The filters enable the user to
select contributor, treatment and disease type on the page’s
left side. Applying the selected filter to the data regener-

ates the Tumor Volume and the Tumor Disease Types figure
tabs. The currently available volume data is from 20 models representing 1 disease type, which were treated with 17
possible agents. The dataset has 10 432 volume measures
from 20 treatment studies. The Tumor Volume tab allows
the user to choose plot level (Animal and Treatment Arm)
and plot pattern (multiple and combined), reorganizing the
plots to correspond to select values. Additionally, under the
‘Tumor Volume – Study’ subtab, users can dynamically generate RECIST response classifications (Figure 4). The RECIST classification calculation is based on combination of
the best response and average response adapted from Gao
et al. (26).
Quality control analysis
The PDXNet portal QC analysis page provides plots and
tabular results for selected QC metrics (Supplementary Figure S7). The page displays QC metrics generated during
the standardized data processing procedure for each relevant data type. The page provides sub-tabs showing wholeexome and RNA-Seq quality control metrics for a selected
dataset PDXNet or PDMR. The whole-exome tabs plot
mean target coverage, percent target bases with >20% coverage, and percent duplication by data contributor. The
RNA-Seq tabs plot percent usable bases, percent ribosomal
bases and percent correct strand reads. The plotted metrics,
along with additional QC metrics are available in a table at
the bottom of the page.
Variant search
The PDXNet Portal Variant Search page allows the user
to search for variants derived from whole exome data pro-
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Figure 3. Examples figures generated from the HRD-TMB-MSI page on the PDXNet Portal Plots generated on the PDXNet Portal HRD-TMB-MSI
page. (A) Plot of Homologous Recombination Deficiency (HRD) computed from sequencing data provided by PDXNet researchers. The plot shows HRD
by disease type. (B) Plot of Tumor Mutational Burden (TMB) computed from sequencing data provided by PDXNet researchers. The plot shows TMB by
disease type. (C) Plot of TMB computed from sequencing data provided by PDXNet researchers, by disease type.
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Figure 4. Tumor volume data page on the PDXNet Portal Components of the PDXNet tumor volume page. The figure shows a filtered dataset. (A) Panel
shows summary statistics including number tumor volume datasets (green), number of models in the selected dataset (yellow), total number of patients
(blue), and total number of diseases represented (red). (B) Panel shows the tumor volume data organized by study and automatically computed resist
category for each treatment arm. (C) Panel shows the tumor volume response and metadata in a spreadsheet format. The interface supports searching and
sorting metadata. Users can copy, print, and download metadata into accessible formats
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cessed using the PDXNet whole exome pipelines on the
CGC. The page allows users to query based on either gene
symbol or chromosome position. For each query, a summary of variant types, variants by gene and SNP types
is shown. The variants returned in the query are available at the bottom of the page. We currently present all
called variants for 491 samples as a beta feature release,
with the ability for the user to further filter results as
needed.
DISCUSSION

DATA AVAILABILITY
Each PDXNet portal data tab allows users to download
metadata. Data for smaller data types such as tumor volume
data and computed metrics (e.g. HRD and TMB) can be
downloaded directly from the portal. For larger data types,
please request data from the PDXNet Portal’s Contact page.
We will coordinate with PDTCs to make data available either directly or through dbGaP as required by the PDXNet
data sharing agreement.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Cancer Online.
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The PDXNet portal is a vital component of the PDXNet
consortium. The portal establishes a mechanism for public discovery of consortium-generated resources including
models, data and workflows. The portal allows researchers
to examine the data, models and metadata using integrated
query features. These portal capabilities facilitate cancer
data discovery, a core goal of the NCI Cancer Moonshot program. Additionally, the PDXNet portal allows the
consortium to manage data analysis projects by clarifying which data are available, their source, their quality and
their suitability for research projects and scientific questions. Within the PDXNet consortium, the PDXNet portal functions as a centralized source of information for the
status of the available models. The standardized sequence
processing, quality control, and computation of common
metrics (e.g. MSI, TMB, HRD and genetic ancestry) further enhance data analysis, model use, prioritization of future models and data collection.
Enhancement of collaboration between researchers is a
main objective of the PDXNet portal. To accomplish this,
we are integrating the PDXNet portal and PDXNet data
with existing NCI, NIH, and NCBI infrastructure. All data
visible on the PDXNet Portal will also be available through
the Cancer Data Service (CDS) through dbGaP (27) access. Accessing PDXNet data on the Cancer Genomics
Cloud (16) allows users to perform sophisticated analyses utilizing cloud computing within an integrated bioinformatics ecosystem. By co-locating data and analysis, as
well as integrating data management, this infrastructure
can decrease the time required for researchers to perform
analyses.
For large consortia such as PDXNet, metadata and secondary data types are often just as important as sequencing data for supporting impactful research. Examples of
these additional data types include high-resolution images
and tumor volume/drug response data. These data extend the types of problems researchers can address. We
expect that the portal’s image and tumor volume functionality will expand as these datasets grow. Future iterations of the portal will include interactive exploration across
data types allowing users to address complex research
problems.
Although PDXs have caveats as a model system, e.g. the
fact that only tumors that successfully engraft can be studied, they are widely used in cancer research. To ensure their
optimal use, continuing attention to standards for data submission, access, and quality is essential. The PDXNet Portal reflects PDXNet activities to implement such standards
not only for sequencing data but also metadata and sec-

ondary data types. Another consideration requiring careful
implementation is to balance data security versus ease of
use. The PDXNet portal will grow with new data and features as the PDXNet consortium continues to generate new
models. Consequently, standardized processing and batch
effects are of increasing concern for downstream analyses.
To ensure that researchers have confidence in the data quality, we will continue to share the informative metrics computed by the standardized PDXNet quality control workflows.
Several key features are the focus for the next iteration
of the PDXNet portal. These include tools to expand our
search features for commonly found genomic variants (e.g.
INDELs and copy number variations) within models, diseases and genes of interest, and interactive exploration of
gene expression data. These tools would enable researchers
to perform meaningful analyses directly from the portal
and more rapidly realize value from PDXNet data. Visualization and analysis of associated data, including imaging
and tumor volume/drug response data, will also be a focus.
These data types have the potential for high impact, particularly given the innovation in large scale data visualization
techniques in many fields.
Further development of links between the PDXNet portal and NCI computational infrastructure will benefit researchers as well. Moving large quantities of data is timeconsuming and can be expensive. Enabling researchers to
perform their analysis where the data is already present
lowers the entry barrier into the computational analysis of
PDX model data. To facilitate these links, we envision users
will be able to create cohorts for analysis using the PDXNet
portal and transferring that selection to the Cancer Genomics Cloud or other computational platform, where they
will be able to easily take advantage of well-developed computational infrastructure.
We will extend PDXNet portal capabilities as the size and
complexity of PDXNet datasets grow. These enhancements
will allow the research community to quickly find and evaluate PDXNet resources to supplement their research studies. We will continue to improve the PDXNet portal value
by collaborating with related PDX initiatives, including the
PDMR, PDXFinder and EuroPDX. Such collaborations
will demonstrate how to effectively conduct studies across
institutions, providing examples for the broader research
community in how to optimize their PDX studies with respect to the public PDX models and datasets that are becoming increasingly available.
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